title: Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer.
abstract: BACKGROUND
  Individuals who had cancer in childhood are at higher risk of developing bone cancer than any other type of second primary cancer.
  
  
  OBJECTIVE
  Using the population-based National Registry of Childhood Tumours in Britain, we investigated the incidence and etiology of second primary bone cancer after childhood cancer in a cohort study and in a case-control study.
  
  
  METHODS
  A cohort study of 13,175 3-year survivors of childhood cancer diagnosed in Britain between 1940 and 1983 revealed 55 subsequent bone cancers. A largely nested case-control study comprised 59 case subjects developing second primary bone cancer, and 220 control subjects were selected and matched for sex, type of first cancer, age at first cancer, and interval between diagnosis of first cancer and subsequent bone cancer. Outcome measures were the incidence of bone cancer after childhood cancer, the cumulative dose of radiation received at the site of the second cancer in the case subject and at the corresponding anatomic site in the matched control subjects, and the cumulative dose of alkylating agents and vinca alkaloids received by case and control subjects.
  
  
  RESULTS
  The percentage of 3-year survivors developing bone cancer within 20 years did not exceed 0.9%, except following heritable retinoblastoma (7.2%), Ewing's sarcoma (5.4%), and other malignant bone tumors (2.4%). The risk of bone cancer increased substantially with increased cumulative dose of radiation to the bone (P< .001, linear trend). At the highest levels of exposure, however, the risk appeared to decline somewhat (P=.065, nonlinearity). Exposure to less than 10 Gy was at worst, associated with only a small increased relative risk (RR) of bone cancer (RR= 0.7; 95% confidence interval = 0.2-2.2). The risk of bone cancer increased linearly (P= .04, one-tailed test) with increased cumulative dose of alkylating agents.
  
  
  CONCLUSIONS
  This population-based study provides grounds for reassurance of the majority of survivors in that their risk of developing bone cancer within 20 years of 3-year survival did not exceed 0.9%. The higher risks found for bone cancer following the other specific rare types of childhood cancer provide a rational basis for surveillance. The RRs reported for bone cancer after specified levels of exposure to radiation should help in making decisions concerning future treatment protocols.
authors.affiliation: Childhood Cancer Research Group, University of Oxford, U.K.
authors.forename: M M
authors.initials: MM
authors.lastname: Hawkins
authors.forename: L M
authors.initials: LM
authors.lastname: Wilson
authors.forename: H S
authors.initials: HS
authors.lastname: Burton
authors.forename: M H
authors.initials: MH
authors.lastname: Potok
authors.forename: D L
authors.initials: DL
authors.lastname: Winter
authors.forename: H B
authors.initials: HB
authors.lastname: Marsden
authors.forename: M A
authors.initials: MA
authors.lastname: Stovall
mesh_terms: D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000209:etiology*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D016609:Neoplasms, Second Primary / Q000209:etiology*; D011878:Radiotherapy / Q000009:adverse effects*; D012175:Retinoblastoma / Q000628:therapy; D012306:Risk; D012512:Sarcoma, Ewing / Q000628:therapy
chemical_list: D018906:Antineoplastic Agents, Alkylating